1. Introduction {#sec1}
===============

Black cohosh (*Cimicifuga racemosa*) is an herbal supplement that is sold over-the-counter for management of menopausal symptoms, menstrual irregularities, and arthritis. There are now a number of manuscripts indicating liver injury from black cohosh \[[@B3]--[@B24]\]. Here, we present two patients who developed a drug-induced liver injury following the use of black cohosh characterized by centrilobular necrosis and histologic features mimicking autoimmune hepatitis (AIH) who improved with corticosteroid therapy.

2. Case Studies {#sec2}
===============

The case series was approved by the Institutional Review Board at the University of Illinois at Chicago.

Case 1A 42-year-old woman presented to her primary care provider with a two-month history of progressive malaise, nausea, vomiting, and dizziness. On physical examination, she had mild icterus and no stigmata of chronic liver disease. Her only comorbidity was hypothyroidism. Her medications included black cohosh, which she was taking for 6 months, and levothyroxine 0.05 mg daily. She discontinued black cohosh when her symptoms began. She had no family history of liver or autoimmune disease. She denied any alcohol or drug use. Her total bilirubin level was 3.1 mg/dL (normal 0.8--1.2), alanine transaminase (ALT) 1457 U/L (normal 5--40), aspartate transaminase (AST) 696 U/L (normal 10--40), alkaline phosphatase (ALP) 94 U/L (normal 30--120 U/L), and international normalized ratio (INR) 1.2 (normal 0.8--1.2). Further laboratories showed no serological evidence of active hepatitis A, B, or C infection. Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative. Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80. Serum iron was 169 *μ*g/dL (normal: 50 to 170 *μ*g/dL for women), ferritin was 642 ng/dL (normal: 15--200 ng/mL for females), and hemochromatosis gene analysis was negative. Ceruloplasmin was in the normal range.Four months after her initial presentation, the liver enzymes remained elevated with an ALT of 334 U/L, AST 229 U/L, and a total bilirubin of 1.4 mg/dL. A liver biopsy was performed which prompted a referral to the liver center at the University of Illinois. The liver biopsy was remarkable for necrosis around terminal hepatic venules, lobular disarray, mild ballooning, apoptosis, Kupffer cell reactivity, mild cholangiolar proliferation, and interface hepatitis remarkable for numerous plasma cells and eosinophils. A repeat antismooth muscle antibody was normal at 1 : 20. Prednisone treatment was initiated. A follow-up liver biopsy was performed after three months. At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures [1(a)](#fig1){ref-type="fig"} and [1(b)](#fig1){ref-type="fig"}). The patient was started on azathioprine. Her liver enzymes returned to normal values within five months with an ALT of 30 U/L, AST of 29 U/L, ALP 36 U/L, and a total bilirubin of 0.9 mg/dL. A repeat liver biopsy after fifteen months showed marked improvement with only minimal portal lymphocytes and no other significant histopathological changes. The liver function test values remained normal at 15 months and at 40 months following the acute episode. The clinicopathological features of [Case 1](#casee1){ref-type="statement"} are illustrated in Tables [1](#tab1){ref-type="table"}, [2](#tab2){ref-type="table"}, and [3](#tab3){ref-type="table"}.

Case 2A 53-years-old woman presented to our liver center for evaluation of elevated liver enzymes detected at a health screening fair four months earlier. She had no risk factors for viral hepatitis, no family history of liver disease, and denied any alcohol consumption. Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation. Her medical history was remarkable only for irritable bowel syndrome. Her medications within the past year included dicyclomine for abdominal cramps as needed, an herbal supplement which contains soy protein and black cohosh for menopausal symptoms, and occasional over the counter nonsteroidal anti-inflammatory drugs (NSAIDs) for pain. She discontinued these medications on the advice of her primary care physician. Laboratories showed a total bilirubin of 2.0 mg/dL, ALT 443 U/L, AST 478 U/L, ALP 188 U/L, and an INR of 2.0. Other notable laboratory values included negative serological evidence of active hepatitis A, B, and C viral infection, undetectable hepatitis C virus RNA by PCR, iron 137 *μ*g/dL, ferritin 1527 ng/mL, negative hemochromatosis gene analysis, and nonsignificant ceruloplasmin level. Serological tests for antinuclear, antismooth muscle, antiliver kidney microsomal, and antimitochondrial antibodies were negative. An ultrasound demonstrated patent portal and hepatic veins and a normal appearing liver. Her liver biopsy was remarkable for centrilobular necrosis with moderate cholangiolar proliferation and plasma cell rich interface and lobular hepatitis.The patient was started on 40 mg of prednisone daily. Liver function test values improved to a total bilirubin of 1.4 mg/dL, ALT of 60 U/L, AST 50 U/L, and ALP 153 U/L after two weeks and normalized after five weeks of therapy. The clinicopathological features of [Case 2](#casee2){ref-type="statement"} are illustrated in Tables [1](#tab1){ref-type="table"}, [2](#tab2){ref-type="table"}, and [4](#tab4){ref-type="table"}.

3. Application of the Naranjo Causality Score for Adverse Drug Reactions {#sec3}
========================================================================

The Naranjo causality score for adverse drug reactions \[[@B17]\] was applied to the cases described here. As shown in [Table 5](#tab5){ref-type="table"}, the current case studies individually achieved a Naranjo score of 3 and were both categorized as "possible adverse drug reaction", in a scale encompassing a minimum score of zero, or "doubtful adverse drug reaction" to a maximum score of ≥9, or "definite adverse drug reaction."

4. Application of the Hennes-Simplified Criteria for Diagnosis of Autoimmune Hepatitis (AIH) {#sec4}
============================================================================================

While the current case studies showed histopathological features of autoimmune hepatitis, neither fulfilled a diagnosis of "probable AIH" or "definite AIH" based on the Hennes simplified criteria for diagnosis of AIH \[[@B8]\]. Briefly, [Case 1](#casee1){ref-type="statement"} had an ANA titer of up to 1 : 80 (score 2), no available immunoglobulin titers (no score), a liver histology compatible with AIH (score 1), and absence of viral hepatitis (score 2), with a total score of 5. [Case 2](#casee2){ref-type="statement"} had a score of 1-0-1-2 = 4, on a scale where a score of ≥6 was designated "probable AIH", and ≥7 as "definite AIH."

5. Discussion {#sec5}
=============

Botanical dietary supplements are used commonly in the United States and are generally perceived to be safe \[[@B12]\]. In one study, nearly one half of persons reported use of at least one agent to their primary provider \[[@B6]\]. A major difficulty in studying black cohosh is uncertainty regarding the composition of the various black cohosh products. Black cohosh itself contains a number of secondary compounds including phenolic derivatives and triterpene glycosides \[[@B9]\]. Phytoestrogens were postulated to play a role in black cohosh binding to estrogen receptors, but the presence of these compounds is controversial. In one study, chromatographic analysis of 11 commercial black cohosh products showed that three were actually Asian *Actea* species \[[@B9]\]. An analysis of the remaining eight products found variability in the composition of triterpene glycosides and phenolic constituents. More importantly, not a single product contained a phytoestrogen. Thus, the mechanism by which black cohosh might impact on alleviating menopausal symptoms is not well understood. Other possibilities include binding to yet-to-be-defined receptors or effects on the central nervous system \[[@B23]\]. Whether black cohosh is effective in controlling vasomotor symptoms of menopause is controversial as well. The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause \[[@B1]\]. A large randomized-blinded trial of one-year duration found no difference between black cohosh and placebo in controlling vasomotor symptoms \[[@B18]\]. Moreover, a recent review did not recommend long-term use due to the absence of safety evaluation \[[@B10]\].

There are a growing number of case reports of hepatotoxicity in patients taking black cohosh ([Table 6](#tab6){ref-type="table"}) \[[@B3]--[@B24]\]. Most described acute hepatic necrosis, although three articles of them detailed a case with clinical features of autoimmune hepatitis after black cohosh use \[[@B3], [@B4], [@B14]\]. The clinicopathological features of the cases in the current series have a fascinating combination of findings. Both patients presented with an acute hepatitis displaying prominent centrilobular necrosis consistent with severe drug-induced liver injury. While autoantibodies were low titer or absent, the histology showed characteristics of autoimmune hepatitis with a plasma cell rich interface and lobular hepatitis. In addition, both patients responded to corticosteroids, supporting an immune mediated component to the liver injury.

Determining the risk of black cohosh hepatotoxicity is further complicated by variability in both dosage and number of other botanical herbal supplements contained in some preparations. As an example, in the case reported by Lontos \[[@B13]\], the preparation of black cohosh included 4 other botanicals: ground ivy, golden seal, gingko, and oat seeds. While liver injury remains unreported with the use of the last 3 botanicals, ground ivy contains a known hepatotoxin, pulegone. This case culminated in liver failure despite discontinuation of the herbal supplement \[[@B13]\].

Drug interactions might further potentiate negative outcomes resulting from hepatoxicity due to herbal supplements. That subjects in 3 of 5 reported cases of autoimmune-like liver injury following consumption of black cohosh ([Table 6](#tab6){ref-type="table"}) also had concomitant intake of synthetic thyroid hormone, levothyroxine, merits attention \[[@B4], [@B14]\]. Herbal supplements such as venencapsan and black cohosh, and prescription drugs specifically rosiglitazone, ritonavir, and valproic acid, have had reported drug interactions with levothyroxine \[[@B3], [@B16], [@B5]--[@B22]\].

A 2008 review by Mahady assigned all known case reports of black cohosh-induced liver injury under the category of "possible causality" \[[@B16]\]. As earlier stated, both cases of the current study were also assigned "possible causality" by Naranjo scale \[[@B17]\]. Although no clinical or animal pharmacokinetic or toxicological information were identified in the Mahady review, it led to the inclusion of a cautionary statement on black cohosh products which was not previously required \[[@B16]\]. Despite such development, the use of botanical dietary supplements is generally viewed by the public as safe \[[@B12]\]. Providers are encouraged to screen patients about their consumption of botanical herbal supplements and to assess for any evidence of liver injury \[[@B3]\]. Timely discontinuation of hepatotoxic agents and, in some cases, early initiation of immunotherapy might prevent significant liver injury or could even be life saving \[[@B13]\].

The validity of reported cases of liver injury due to black cohosh illustrated in [Table 6](#tab6){ref-type="table"}has been disputed. Concerns that led to this uncertainty included cases in which the timing of liver injury occurred at a relatively short interval following exposure to black cohosh \[[@B4], [@B19], [@B24]\], presence of comorbidities such as cholelithhiasis \[[@B19]\] or concomittant use of drugs other than black cohosh that could have potentially triggered the adverse drug reaction \[[@B11], [@B13], [@B24]\], or the notion that some of the reported cases \[[@B4]\], including [Case 1](#casee1){ref-type="statement"} of the current study (also reported by Mahady \[[@B15]\]), were indeed examples of autoimmune hepatitis rather than adverse drug reactions. Nonetheless, application of the Naranjo causality score to these case reports found possible cause for adverse drug reaction \[[@B17]\]. Further, autoimmune hepatitis is one of the known outcomes of drug-induced liver injury. The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen \[[@B2]\] and thereby eliciting an autoimmune response. Outcomes illustrating an association of chronic hepatitis with autoimmune features developing following the use of the botanical supplement black cohosh need to be emphasized.

6. Conclusion {#sec6}
=============

Here we described two cases of liver injury following the use of black cohosh characterized by chronic hepatitis with centrilobular necrosis and an interface activity dominated by plasma cells. While the histopathology in both cases was compatible with autoimmune hepatitis, clinical evidence for an autoimmune etiology was lacking. Nonetheless both cases improved upon withdrawal of the drug and immunosuppressive therapy, indicating that there was at least in part a drug-induced immunological basis to the liver injury.

The current case studies, and three other published cases of liver injury following the use of black cohosh, share similar histological characteristics \[[@B3], [@B4], [@B14]\]. Hepatic manifestations following the use of black cohosh should therefore be added to the list of differential diagnoses of hepatic necrosis culminating in chronic hepatitis mimicking autoimmune hepatitis.

![This liver biopsy from [Case 1](#casee1){ref-type="statement"} displays chronic hepatitis remarkable for its dense interface activity with cholangiolar proliferation (1a) (×200) and sheets of plasma cells and apoptosis (1b) (×600).](CRM2009-918156.001){#fig1}

###### 

Current case studies: clinical features and medications.

  Clinical features   Case 1                        Case 2
  ------------------- ----------------------------- ---------------------------------
  Age (years)         42                            53
  Gender              Female                        Female
  Signs               Mild icterus                  Increased LFTs
  Symptoms            Progressive malaise, nausea   RUQ\*\* abdominal pain, fatigue
                      Vomiting, dizziness           Lower extremity edema
  Stigmata of CLD     Absent                        Absent
                                                    
  Medications         Black cohosh                  OTC with soy and black cohosh
                                                    
  Indication          Menopausal symptoms           Menopausal symptoms
  Dose                Not specified                 Not specified
  Duration            6 months                      8 months
                                                    
  Other medications   Levothyroxine                 Dicyclomine; NSAID
                                                    
  Indication          Hyperthyroidism               GI cramps; pain
  Dose                0.05 mg daily                 Not specified
  Duration            Chronic                       As needed

LFTs: Liver function tests.

RUQ: Right upper quadrant.

CLD: Chronic liver disease.

OTC: Over the counter drug.

NSAID: Nonsteroidal anti-inflammatory drug.

###### 

Current case studies: past medical history, serological tests, and other pertinent laboratory data.

                                                                                        Case 1        Case 2
  ------------------------------------------- ----------------------------------------- ------------- -------------
  Past medical history                        Viral or non-viral hepatitis              Absent        Absent
  Alcohol consumption                         Absent                                    Absent        
                                                                                                      
  Serological tests                           Anti-HAV IgM                              Absent        Absent
  Anti-HAV total                              Absent                                    Absent        
  HBV surface antigen                         Absent                                    Absent        
  Anti-HBV core                               Absent                                    Absent        
  Anti-HBV surface                            Absent                                    Absent        
  Anti-HCV                                    Absent                                    Absent        
  EBV Ca IgM                                  Absent                                    Absent        
  EBV Ca IgG                                  Absent                                    Absent        
  EBV Na IgG                                  Absent                                    Absent        
  EBV IgG                                     Absent                                    Absent        
  Anti-CMV IgM                                Absent                                    Absent        
                                                                                                      
  HCV RNA PCR                                                                           Negative      Negative
                                                                                                      
  Other laboratory values                     Iron (normal: 50--70 *μ*g/dL for women)   169 *μ*g/dL   137 *μ*g/dL
  Ferritin (normal: 15--200 ng/mL in women)   642 ng/mL                                 1527 ng/mL    
  HFE gene analysis                           Negative                                  Negative      
  Ceruloplasmin                               Normal                                    Normal        

###### 

Duration of Illness and black cohosh use, liver function tests, autoimmune markers, histology, and treatment.

  Case 1                                                                                                                                          
  --------------------------------------------- -------- -------------------------------- ------------------- ------ ---------------------------- ------
  *Time of use to illness:* 6 mo\*\*↓                                                                                                             
                                                                                                                                                  
  *Time of use to discontinuation:* 6 mo\*\*↓                                                                                                     
                                                                                                                                                  
  *Time of presentation to the liver*clinic\*            \*↓                                                                                      
                                                                                                                                                  
  *Duration of illness in months*               2        4                                7                   12     15                           40
  *Treatment*                                   ---      Prednisone                       Azathioprine        ---    ---                          ---
                                                                                                                                                  
  *Liver function tests (normal)*                                                                                                                 
   Total bilirubin (0.8--1.2 mg/dL)             3.1      1.4                              1.8                 0.9    1.0                          0.8
   ALT (5--40 U/L)                              1457     334                              321                 30     39                           37
   AST (10--40 U/L)                             696      229                              236                 29     37                           33
   ALP (30--120 U/L)                            94       68                               66                  36     38                           37
    *INR* (0.8--1.2)                            1.2      1.17                             ---                 0.95   ---                          0.92
                                                                                                                                                  
  *Autoimmune antibodies*                                                                                                                         
   Antinuclear antibody                         1 : 40   1 : 20                           ---                 ---    ---                          ---
   Antismooth muscle antibody                   1 : 80   ---                              ---                 ---    ---                          ---
    *Liver biopsy findings*                     ---      Acute hepatitis                  Chronic hepatitis   ---    Biopsy at 15 mo.             
                                                                                                                                                  
  *Lobular*                                                                                                                                       
   Necrosis                                     ---      Central & portal                 ---                 ---    Absent                       
   Infiltrates                                  ---      Mixed with eosinophils           Plasmacytic         ---    Absent                       
   Other findings                               ---      Disarray, ballooning Apoptosis                       ---    No significant abnormality   
                                                                                                                                                  
  *Portal and periportal*                                                                                                                         
   Cholangiolar proliferation                   ---      Moderate                         Moderate            ---    Absent                       
   Infiltrate severity                          ---      Moderate                         Moderate            ---    Minimal                      
   Infiltrate predominant type                  ---      Mixed with eosinophils           Plasmacytic         ---    Lymphocytes                  
    *Fibrosis*                                  ---      Fibronecrosis                    Fibronecrosis       ---    Absent                       

###### 

Duration of Illness and black cohosh use, liver function tests, autoimmune markers and histology.

  Case 2                                                                                 
  --------------------------------------------------- --------------------- ------------ -----
  *Time of use to illness: 8 m o n t h s*\*           \*↓                                
                                                                                         
  *Time of use to discontinuation: 8 m o n t h s*\*   \*↓                                
                                                                                         
  *Time of presentation to liver c l i n i c*\*                             \*↓          
                                                                                         
  *Duration in months*                                4                     4.5          5
                                                                                         
  *Treatment*                                                               Prednisone   
                                                                                         
  *Liver function tests (normal values)*                                                 
   Total bilirubin (0.8--1.2 mg/dL)                   2.0                   1.4          0.6
   ALT (5--40 U/L)                                    443                   60           30
   AST (10--40 U/L)                                   478                   50           38
   ALP (30--120 U/L)                                  188                   153          98
    *INR* (0.8--1.2)                                  2.0                   ---          1.3
                                                                                         
  *Autoimmune antibodies*                                                                
   Anti-nuclear antibody                              Negative              1 : 20       ---
   Anti-smooth muscle antibody                        Negative              ---          ---
    *Liver biopsy findings*                                                 ---          ---
                                                                                         
  *Lobular*                                                                              
   Necrosis                                           Central               ---          ---
   Infiltrates                                        Plasmacytic           ---          ---
   Other findings                                     Disarray, apoptosis   ---          ---
                                                                                         
  *Portal and periportal*                                                                
   Cholangiolar proliferation                         Moderate              ---          ---
   Infiltrate severity                                Moderate              ---          ---
   Infiltrate predominant type                        Plasmacytic           ---          ---
    *Fibrosis*                                        Fibronecrosis         ---          ---

###### 

Naranjo \[[@B17]\] Causality Scale for Adverse Drug Reactions.

  Question/Scoring-Yes/No/Do not know or unavailable   Case 1                                                                                                                    Case 2   
  ---------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- -------- ----
  1                                                    Are there previous conclusive reports on this reaction? 1/0/0                                                             0        0
  2                                                    Did the adverse event appear after the suspected drug was given? 2/−1/0                                                   2        2
  3                                                    Did the adverse reaction improve when the drug was discontinued or a specific antagonist was given? 1/0/0                 1        1
  4                                                    Did the adverse reaction appear when the drug was readministered? 2/−1/0                                                  0        0
  5                                                    Are there alternative causes that could have caused the reaction? −1/2/0                                                  −1       −1
  6                                                    Did the reaction reappear when a placebo was given? −1/1/0                                                                0        0
  7                                                    Was the drug detected in any body fluid in toxic concentrations? 1/0/0                                                    0        0
  8                                                    Was the reaction more severe when the dose was increased/ increasing, or less severe when the dose was decreased? 1/0/0   1        1
  9                                                    Did the patient have a similar reaction to the same or similar drugs in any previous exposure? 1/0/0                      0        0
                                                                                                                                                                                          
                                                             Total score                                                                                                         3        3

Scoring: \>9 : definite adverse drug reaction (ADR).

5--8 : probable ADR.

1--4 : possible ADR.

0 : doubtful ADR.

###### 

Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.

  Case reports                                             Whiting Case 1\*           Whiting Case 2\*                                    Lontos\*                                                    Levitsky\*                                 Cohen\*                Lynch\*                Chow                                         Nisbet                             Current study Case 1^\#\#^     Current study Case 2
  -------------------------------------------------------- -------------------------- --------------------------------------------------- ----------------------------------------------------------- ------------------------------------------ ---------------------- ---------------------- -------------------------------------------- ---------------------------------- ------------------------------ -------------------------------
  Age/gender                                               47F                        43F                                                 52F                                                         50F                                        57F                    54F                    51F                                          50F                                42F                            53F
                                                                                                                                                                                                                                                                                                                                                                                                              
  Botanical dietary contents                               Black cohosh               Black cohosh, skullcap\#, Valerean, Passionflower   Black cohosh, ground ivy\#, golden seal, Gingko, oat seed   Black cohosh                               Black cohosh           Black cohosh           Black cohosh                                 Black cohosh                       Black cohosh                   Black cohosh, soy
                                                                                                                                                                                                                                                                                                                                                                                                              
  Other drugs                                                                                                                                                                                                                                    Levothyroxine          Levothyroxine                                                                                          Levothyroxine                  Dicyclomine
                                                                                                                                                                                                                                                                                                                                                                                                              
  Serologies indicating presence of other liver diseases                                                                                                                                              Absent                                                            Absent                 Absent                                                                          Absent                         Absent
                                                                                                                                                                                                                                                                                                                                                                                                              
  Lab data indicating presence of other liver diseases                                                                                                                                                Absent                                                            Absent                 Absent                                                                          Absent                         Absent
                                                                                                                                                                                                                                                                                                                                                                                                              
  Presenting symptom                                       Jaundice                                                                       ALF                                                         ALF                                                               ALF                    Jaundice                                     Acute hepatitis                    Acute hepatitis                RUQ pain
                                                                                                                                                                                                                                                                                                                                                                                                              
  Main liver biopsy finding                                                                                                                                                                           Acute hepatitis                                                   Acute hepatitis        Massive liver necrosis                                                          Centrilobular necrosis         Centrilobular necrosis
                                                                                                                                                                                                                                                                                                                                                                                                              
  Lobular infiltrate                                                                                                                                                                                                                                                    Mixed + plasma cells   Mononuclear infiltrate                                                          Plasma cytic infiltrate        Lymphop-lasmacytic infiltrate
  Other lobular findings                                                                                                                                                                              Necrosis                                                          Bridging necrosis      Preserved bile ducts, collapsed parenchyma                                      Lobular disarray               Lobular disarray
                                                                                                                                                                                                                                                                                                                                                                                                              
  Therapy                                                                                                                                                                                             Prednisone                                 Immuno-therapy         Prednisone                                                                                             Prednisone & azathioprine      Prednisone
                                                                                                                                                                                                                                                                                                                                                                                                              
  Intervention                                             OLT                                                                                                                                        OLT                                                               OLT                    OLT                                          Withdrawal of black cohosh         Withdrawal of black cohosh     Withdrawal of black cohosh
                                                                                                                                                                                                                                                                                                                                                                                                              
  Outcome                                                                             Recovery                                            LF s/p d/c black cohosh                                     Recovery                                   Recovery               LF death hemorrhage    Recovery                                     Recovery                           Recovery                       Recovery
  AIH like histology                                                                                                                                                                                                                             Present                Present                Present                                                                         Present                        Present
                                                                                                                                                                                                                                                                                                                                                                                                              
  Serological marker for AIH                                                                                                                                                                          Absent                                     Absent                 Absent                 Absent                                                                          Absent                         Absent
                                                                                                                                                                                                                                                                                                                                                                                                              
  Issues disputing validity of black cohosh hepatoxicity   Drug use for only 6 days   Multi-drug product                                  Multi-drug product                                          Multi drug use Ethanol, NSAID & cyclovir   7 day use; maybe AIH                                                                       2 weeks exposure; cholelithiasis   Maybe AIH                      

\*Cases adapted from [Table 1](#tab1){ref-type="table"}Lynch \[[@B14]\]; ALF: Acute liver failure; RUQ: Right upper quadrant pain.

OLT: Orthotopic liver transplant; LF: Liver failure.

^\#^Herbal remedies known as hepatotoxic; ^\#\#^Also reported by Mahady \[[@B16]\]; AIH: Autoimmune hepatitis.

[^1]: Recommended by Anne M. Larson
